{
    "clinical_study": {
        "@rank": "163071", 
        "arm_group": [
            {
                "arm_group_label": "clopidogrel-ticagrelor", 
                "arm_group_type": "Experimental", 
                "description": "21 days clopidogrel followed by 21 days ticagrelor"
            }, 
            {
                "arm_group_label": "ticagrelor-clopidogrel", 
                "arm_group_type": "Experimental", 
                "description": "ticagrelor for 21 days followed by clopidogrel for 21 days"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is to assess the function of blood vessels while being treated with different\n      types of blood thinners to determine the effect of these medications on blood vessels."
        }, 
        "brief_title": "Effect of Ticagrelor on Endothelial Function", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Coronary Artery Disease", 
            "Endothelial Function"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Age>18 years old\n\n          2. At least two cardiovascular risk factors\n\n          3. Demonstrated endothelial dysfunction\n\n          4. Evidence of coronary artery disease\n\n        Exclusion Criteria:\n\n          1. Second (II) or third (III) degree heart block without a pacemaker\n\n          2. Known  active pathological bleeding, history of stroke, or bleeding diathesis\n\n          3. Dyspnea classified as NYHA class III-IV\n\n          4. Need for  oral anticoagulants\n\n          5. Clinically significant valvular heart disease\n\n          6. Any concurrent life threatening condition with a life expectancy less than 1 year\n\n          7. History or evidence of drug or alcohol abuse within the last 12 months\n\n          8. Any surgical or medical condition, which in the opinion of the investigator, may\n             place the patient at higher risk from his/her participation in the study, or is\n             likely to prevent the patient from complying with the requirements of the study or\n             completing the study\n\n          9. History of hypersensitivity to any of the study drugs or to medications belonging to\n             the same therapeutic class as the study drugs as well as known or suspected\n             contraindications to the study drugs.\n\n         10. Latex allergy\n\n         11. History of noncompliance to medical regimens or unwillingness to comply with the\n             study protocol\n\n         12. Use of other investigational drugs at the time of enrollment, or within 30 days or 5\n             half-lives of enrollment, whichever is longer Positive pregnancy test, breast feeding\n             women or women of child bearing potential not using highly effective methods of\n             contraception.\n\n         13. Patients who are also taking strong CYP3A4 inhibitors (e.g., ketoconazole,\n             clarithromycin, nefazodone, ritonavir, and atazanavir)\n\n         14. patients taking antiplatelet medications which cannot be stopped\n\n         15. severe liver disease"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "45", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01805596", 
            "org_study_id": "ENTC-18129"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "clopidogrel-ticagrelor", 
                    "ticagrelor-clopidogrel"
                ], 
                "intervention_name": "clopidogrel", 
                "intervention_type": "Drug", 
                "other_name": "Plavix"
            }, 
            {
                "arm_group_label": [
                    "clopidogrel-ticagrelor", 
                    "ticagrelor-clopidogrel"
                ], 
                "intervention_name": "Ticagrelor", 
                "intervention_type": "Drug", 
                "other_name": "Brilinta"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Clopidogrel", 
                "Platelet Aggregation Inhibitors", 
                "Ticagrelor"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "coronary artery disease", 
            "endothelial function", 
            "antiplatelet agent"
        ], 
        "lastchanged_date": "May 8, 2013", 
        "location": {
            "contact": {
                "email": "shahar.lavi@lhsc.on.ca", 
                "last_name": "Shahar Lavi, MD", 
                "phone": "519-663-3611"
            }, 
            "contact_backup": {
                "email": "sabrina.dalfonso@lhsc.on.ca", 
                "last_name": "Sabrina D'Alfonso, MSc", 
                "phone": "519-685-8500", 
                "phone_ext": "34807"
            }, 
            "facility": {
                "address": {
                    "city": "London", 
                    "country": "Canada", 
                    "state": "Ontario", 
                    "zip": "N6A5A5"
                }, 
                "name": "London Health Sciences Centre"
            }, 
            "investigator": {
                "last_name": "Shahar Lavi, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effect of Ticagrelor on Endothelial Function", 
        "overall_contact": {
            "email": "shahar.lavi@lhsc.on.ca", 
            "last_name": "Shahar Lavi, MD", 
            "phone": "519-663-3611"
        }, 
        "overall_contact_backup": {
            "email": "sabrina.dalfonso@lhsc.on.ca", 
            "last_name": "Sabrina D'Alfonso, MSc", 
            "phone": "519-685-8500", 
            "phone_ext": "34807"
        }, 
        "overall_official": {
            "affiliation": "London Health Sciences Centre", 
            "last_name": "Shahar Lavi, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The change in endothelial function from baseline will be assessed after 21 days of   clopidogrel; the change in endothelial function from baseline will be assessed after 21 days of ticagrelor.  This will be measured using RH-PAT units.", 
            "measure": "Change from Baseline in Endothelial Function after 21 days of antiplatelet medication", 
            "safety_issue": "No", 
            "time_frame": "21 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01805596"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Lawson Health Research Institute", 
            "investigator_full_name": "Shahar Lavi", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Lawson Health Research Institute", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Lawson Health Research Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}